title: Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
authors.affiliation: Translational Research Institute for Metabolism and Diabetes, Florida Hospital Diabetes Institute, Sanford Burnham Prebys Medical Discovery Institute , Orlando, Florida.
authors.forename: Richard E
authors.initials: RE
authors.lastname: Pratley
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D008687:Metformin / Q000627:therapeutic use; D000097789:Glucagon-Like Peptide-1 Receptor Agonists
chemical_list: D007004:Hypoglycemic Agents; D008687:Metformin; D000097789:Glucagon-Like Peptide-1 Receptor Agonists